Definium Therapeutics' LSD-based treatment, DT120, has shown success in reducing symptoms of generalized anxiety disorder in a late-stage trial.
A single 100-microgram dose of DT120 reduced anxiety scores by 9.8 points after 12 weeks.
Key Takeaways
Center
Not enough sources yet on this side — a blindspot summary will appear once outlets cover the story.
Not enough sources yet on this side — a blindspot summary will appear once outlets cover the story.
Get every side of the week's biggest story in your inbox.
DT120 could provide a new treatment option for generalized anxiety disorder
No attributed perspective yet — we only show quotes grounded in analysis.
Evaluated across 1 reporting source (0% Left · 100% Center · 0% Right)
Historical editorial baseline for Jerusalem Post (IL)
Multi-factor accuracy index for Jerusalem Post (IL) and related desks based on verifiable sourcing and editorial standards.
Factuality: High 100%
Ownership: Jerusalem Post (IL) (Corporate)
Public conversation related to this story
Loading comments…